Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
Golub Capital delivered another year of "good boring," consistent results for its stakeholders in 2025, aided by its commitment to specialization.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback